Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC

NCT05448781 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer
Endostatin

Interventions

DRUG: Endostatin

Sponsor

Affiliated Cancer Hospital & Institute of Guangzhou Medical University